Your browser doesn't support javascript.
loading
Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature.
Gruel, Yves; Vayne, Caroline; Rollin, Jérôme; Weber, Pierre; Faille, Dorothée; Bauters, Anne; Macchi, Laurent; Alhenc-Gelas, Martine; Lebreton, Aurélien; De Maistre, Emmanuel; Voisin, Sophie; Gouilleux-Gruart, Valérie; Perrin, Julien; Tardy-Poncet, Brigitte; Elalamy, Ismail; Lavenu-Bombled, Cécile; Mouton, Christine; Biron, Christine; Ternisien, Catherine; Nedelec-Gac, Fabienne; Duchemin, Jérôme; De Raucourt, Emmanuelle; Gouin-Thibault, Isabelle; Rugeri, Lucia; Tardy, Bernard; Giraudeau, Bruno; Bejan-Angoulvant, Théodora; Pouplard, Claire.
Afiliación
  • Gruel Y; EA 7501, GICC, Université de Tours, Tours, France.
  • Vayne C; Service d'Hématologie-Hémostase, CHRU Tours, Tours, France.
  • Rollin J; EA 7501, GICC, Université de Tours, Tours, France.
  • Weber P; Service d'Hématologie-Hémostase, CHRU Tours, Tours, France.
  • Faille D; EA 7501, GICC, Université de Tours, Tours, France.
  • Bauters A; Service d'Hématologie-Hémostase, CHRU Tours, Tours, France.
  • Macchi L; Service d'Hématologie-Hémostase, CHRU Tours, Tours, France.
  • Alhenc-Gelas M; Laboratoire d'Hématologie, Hôpital Bichat, Paris, France.
  • Lebreton A; Département d'Hémostase et Transfusion, CHU Lille, Lille, France.
  • De Maistre E; Laboratoire d'Hématologie, CHRU Angers, Angers, France.
  • Voisin S; Laboratoire d'Hématologie, HEGP Paris, Paris, France.
  • Gouilleux-Gruart V; Laboratoire d'Hématologie, CHRU Clermont-Ferrand, Clermont-Ferrand, France.
  • Perrin J; Laboratoire d'Hématologie, CHRU Dijon, Dijon, France.
  • Tardy-Poncet B; Laboratoire d'Hématologie, CHRU Toulouse, Toulouse, France.
  • Elalamy I; EA 7501, GICC, Université de Tours, Tours, France.
  • Lavenu-Bombled C; Laboratoire d'Immunologie, CHRU Tours, Tours, France.
  • Mouton C; Laboratoire d'Hématologie, CHRU Nancy, Nancy, France.
  • Biron C; Laboratoire d'Hématologie, CHRU Saint-Etienne, Saint-Etienne, France.
  • Ternisien C; Laboratoire d'Hématologie, Hôpital Tenon, Paris, France.
  • Nedelec-Gac F; Laboratoire d'Hématologie, Hôpital Henri Mondor, Créteil, France.
  • Duchemin J; Laboratoire d'Hématologie, CHRU Bordeaux, Bordeaux, France.
  • De Raucourt E; Laboratoire d'Hématologie, CHRU Montpellier, Montpellier, France.
  • Gouin-Thibault I; Laboratoire d'Hématologie, CHRU Nantes, Nantes, France.
  • Rugeri L; Laboratoire d'Hématologie, CHRU Rennes, Rennes, France.
  • Tardy B; Laboratoire d'Hématologie, CHRU Poitiers, Poitiers, France.
  • Giraudeau B; Laboratoire d'Hématologie, Hopital Beaujon, Clichy, France.
  • Bejan-Angoulvant T; Laboratoire d'Hématologie, Hopital Cochin, Paris, France.
  • Pouplard C; Laboratoire d'Hématologie, CHRU Lyon, Lyon, France.
Thromb Haemost ; 120(7): 1096-1107, 2020 Jul.
Article en En | MEDLINE | ID: mdl-32572863
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatments, and only a few large patient cohorts have been reported. In this study, biological and clinical data from 144 French patients with HIT were analyzed in comparison with the literature. METHODS: The diagnosis of HIT was confirmed in all patients by an immunoassay combined with serotonin release assay. In the literature, only cohorts of at least 20 HIT patients published from 1992 were selected for a comparative analysis. RESULTS: Two-thirds of patients were hospitalized in surgery and most were treated with unfractionated heparin (83.2% vs. 16.8% with low molecular weight heparin only). Thrombotic events in 54 patients (39.7%) were mainly venous (41/54). However, arterial thrombosis was more frequent after cardiac surgery (13.2% vs. 2.4% in other surgeries, p = 0.042) with a shorter recovery time (median = 3 vs. 5 days, p < 0.001). The mortality rate was lower in our series than in the 22 selected published studies (median = 6.3% vs. 15.9%). Three genetic polymorphisms were also studied and homozygous subjects FcγRIIA RR were more frequent in patients with thrombosis (37.8 vs. 18.2% in those without thrombosis, p = 0.03). CONCLUSION: This study shows that the mortality rate due to HIT has recently decreased in France, possibly due to earlier diagnosis and improved medical care. It also confirms the strong association between polymorphism FcγRIIA H131R and thrombosis in HIT.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trombocitopenia / Heparina / Anticoagulantes Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Thromb Haemost Año: 2020 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trombocitopenia / Heparina / Anticoagulantes Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Thromb Haemost Año: 2020 Tipo del documento: Article País de afiliación: Francia